In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Crude awakening: Kapoor’s renewable-material protest art installed on Shell gas platform
In the North Sea, protest art made by Anish Kapoor, using renewable materials such as used coffee grounds and beetroot powder, has been installed...
Tiny Vinyl to release tiny, biobased PVC records
In the US, a startup called Tiny Vinyl has created cute, mini, vinyl records out of bio-attributed polyvinyl chloride. The 4-inch mini singles play...
Fun with Fungi: Japanese designers create mycelium block-growing kit
In Japan, designers have created a biomaterial kit for growing toy blocks out mycelium. Dubbed MYMORI, the kit includes block molds and a mycelium...